The Knight ADRC has supported many investigators at Washington University and at other institutions over the years. We wish to avoid the situation where two investigators study the same research question to avoid duplication of effort and potential conflict. To determine if your topic has already been studied with our resources, please search our database. If you find that your topic or a related topic has been submitted, you may wish to contact the investigator to inquire about their findings to determine how you might proceed. You may wish to collaborate or modify your request to avoid overlap. The results below reflect requests made since online requests have been accepted. As such, not all fields will have data as certain information, such as aims, were not collected until recently. If an entry has been assigned an ID number (e.g. T1004), the full request has been submitted and is either approved, disapproved or in process. If an entry has no ID number, then it represents a submission that has not yet been reviewed. Search terms are applied across an entire requests application including variables not displayed below. A more specific, detailed search may yield better results depending upon your needs.
Search Terms:
Investigator: Kaleigh Roberts
Project Title: Precision Neuropathology: Proteomic Clustering of Amyloid Plaques
Date: October 15, 2026 at 5:44 pm
Request ID:
Aim 1: Generate high-resolution spatial proteomic maps of amyloid plaques using CellScape multiplex imaging.
Aim 2: Identify molecularly distinct plaque subtypes using SuStaIn progression modeling and expand proteomic characterization with GeoMx to discover novel subtype biomarkers.
Aim 3: Correlate plaque molecular stages with neuropathologic and clinical measures.
Aim 4:
Investigator: Beika Zhu
Project Title: Characterize microglial ADGRG1 signaling in human Alzheimer’s disease brain
Date: October 13, 2026 at 4:43 pm
Request ID:
Aim 1: To test our hypothesis that the ADGRG1-RhoA-MYC signaling axis slows disease progression in AD patients, we will immunostain dorsolateral prefrontal cortex sections from individuals with no AD pathology, mild cognitive impairment (MCI) or AD (4 male and 4 female per group).
Aim 2:
Aim 3:
Aim 4:
Investigator: LI
Project Title: Defining CEBPB Control of Disease-Associated Microglial States in Alzheimer’s Disease
Date: October 5, 2026 at 10:37 am
Request ID:
Aim 1: Aim 1: Determine whether CEBPB is required for the disease-associated microglial state in vivo.
Aim 2: Aim 2: Determine whether CEBPB controls conserved AD-associated programs in human microglia.
Aim 3:
Aim 4:
Investigator: Lindsay Farrer
Project Title: Alzheimer Disease Genetic Architecture in African Americans
Date: September 30, 2026 at 11:45 am
Request ID:
Aim 1: Identify AD-associated genetic variants and their interaction with known environmental risk factors in AAs and extend/generalize top-ranked results to other population ancestry groups.
Aim 2: Generate and analyze GWAS, transcriptomic, epigenetic, lipidomic and proteomic data in tissue from 325 AA brain donors to discover novel genes, genetic mechanisms and biomarkers for AD in AAs.
Aim 3: Evaluate associations of genetic and multi-omic markers with AD-related neuropathological traits in tissue from 325 AA brain donors.
Aim 4:
Investigator: Soumya Mukherjee
Project Title: Proteomic Analysis of insoluble vascular fractions in cerebral amyloid angiopathy (CAA)
Date: September 16, 2026 at 1:25 pm
Request ID: T2404-A
Aim 1: Perform high throughput mass spectrometry-based proteomics in the Knight ADRC tissue samples with confirmed postmortem neuropathologic changes for CAA
Aim 2: Measure the PTMs of the most enriched proteins (ApoE) in CAA
Aim 3:
Aim 4:
Investigator: Eric McDade
Project Title: Amyloid Clearance and Co-Pathologies in Patients Treated with Lecanemab
Date: August 10, 2026 at 9:22 pm
Request ID: T2612
Aim 1: To identify the extent of Amyloid Beta clearance from post-mortem brain tissue of individuals treated with lecanemab in the Washington University Memory Diagnostic Clinic
Aim 2: To explore the relative persistence of neurofibrillary tau (NFT) pathology, and the characterization of non-AD co-pathologies—specifically phosphorylated tau, a-synuclein, and phosphorylated TDP-43—in the setting of long-term ATT clinical administration
Aim 3: To compare AD Core and related pathology in those treated with lecanemab to similarly staged participants with AD and Controls (low AD pathological burden) from the Knight ADRC Brain Bank
Aim 4:
Investigator: Nikolaos Mellios
Project Title: Replication of 34-circular RNA Blood-Based Biomarkers for Alzheimer’s from Knight Alzheimer Disease Research Center
Date: May 12, 2026 at 6:36 pm
Request ID: T2611
Aim 1: Replicate circRNA biomarker measurements associated with AD in the Knight ADRC discovery cohort with RNA seq and digital droplet PCR.
Aim 2: Validate circRNA biomarker performance for AD diagnosis and progression in the independent Knight ADRC replication cohort.
Aim 3:
Aim 4:
Investigator: Ozioma Okonkwo
Project Title: Cognitive Resilience in AD
Date: May 11, 2026 at 1:01 pm
Request ID: T2610
Aim 1: This is a request initiated on behalf of Ozioma Okonkwo for a pending R01 grant submission related to cognitive resilience. WashU will serve as a site (Justin Long as co-investigator). The goal at this stage is to request cohort/specimen numbers in support of the grant submission.
Aim 2:
Aim 3:
Aim 4:
Investigator: Xiao-Jun Ma
Project Title: NULISA IVD Assay Development
Date: May 1, 2026 at 7:14 pm
Request ID: T2608
Aim 1: To evaluate and establish clinical performance of the BD-pTau217 assay.
Aim 2:
Aim 3:
Aim 4:
Investigator: Li-Huei Tsai
Project Title: Investigating Lipidomic Perturbations in the CSF with Age and Alzheimer’s Disease Progression: Toward Mechanistic Insights and Accessible Lipid Biomarkers
Date: April 15, 2026 at 7:12 am
Request ID:
Aim 1: We propose to perform lipidomic analysis of the CSF of late-onset Alzheimer’s disease (LOAD) patients and controls to identify biomarkers for LOAD risk and gain mechanistic insights into the role of lipid disturbances in the development of LOAD.
Aim 2:
Aim 3:
Aim 4: